Table 2.
Results of qualitative evaluation.
| Evaluated Vessel Segments | Vessel Visualization (1–4) | Saturation Artifacts(1–4) | ||||
|---|---|---|---|---|---|---|
| TOF | PCASL | PCASL-TOF* | TOF | PCASL | PCASL-TOF* | |
| Anterior cerebral artery | 3.25 | 3.10 | −0.15 | 3.20 | 3.25 | 0.05 |
| Right posterior cerebral artery | 3.22 | 3.11 | −0.11 | 3.22 | 3.06 | −0.16 |
| Left posterior cerebral artery | 3.10 | 3.05 | −0.05 | 3.15 | 3.05 | −0.10 |
| Right middle cerebral artery | 3.35 | 3.30 | −0.05 | 3.35 | 3.25 | −0.10 |
| Left middle cerebral artery | 3.35 | 3.30 | −0.05 | 3.35 | 3.25 | −0.10 |
| Basilar tip | 3.40 | 3.45 | 0.05 | 3.35 | 3.50 | 0.15 |
| Right siphon | 3.30 | 3.60 | 0.30 | 3.30 | 3.85 | 0.55 |
| Left siphon | 3.25 | 3.60 | 0.35 | 3.30 | 3.85 | 0.55 |
| Pathology | 2.80 | 3.50 | 0.70 | 3.00 | 3.60 | 0.60 |
| All the above vessels excluding pathology | 3.28 | 3.32 | 0.04 | 3.28 | 3.39 | 0.11 |
*
Score difference between PCASL-VIPR and 3D TOF. Positive values mean better performance of PCASL-VIPR over 3D TOF, negative values mean the opposite. Statistical significance as tested using a Wilcoxon signed rank test is indicated in bold font (P < 0.05)